Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 2, 2015, Pages 115-127.e15

  Quintás Cardama, Alfonso ^a   Zhang, Nianxiang ^b   Qiu, Yi Hua ^a   Post, Sean ^a   Creighton, Chad J ^c   Cortes, Jorge ^a   Coombes, Kevin R ^b   Kornblau, Steven M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

AML; Proteomics; Reverse phase protein array; RPPA; TRIM62

Indexed keywords

ANTINEOPLASTIC AGENT; BOTULINUM TOXIN; CD135 ANTIGEN; CD34 ANTIGEN; CYTARABINE; FIBRONECTIN; GLUCOSE REGULATED PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NUCLEOPHOSMIN; TRIM62 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CELL ADHESION; CELL MOTILITY; CONTROLLED STUDY; DISEASE DURATION; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; LEUKEMIA REMISSION; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; TRIM62 GENE; TUMOR SUPPRESSOR GENE; VIRUS ONCOGENE; BIOSYNTHESIS; DEFICIENCY; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; PROTEOMICS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEOMICS; SURVIVAL RATE; UBIQUITIN-PROTEIN LIGASES; YOUNG ADULT;

EID: 84921684372     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.07.011     Document Type: Article

References (46)

1. S. Nisole, J.P. Stoye, and A. Saib TRIM family proteins: retroviral restriction and antiviral defence Nat Rev Microbiol 3 2005 799 808
2. A. Reymond, G. Meroni, and A. Fantozzi The tripartite motif family identifies cell compartments EMBO J 20 2001 2140 2151
3. M. Sardiello, S. Cairo, B. Fontanella, A. Ballabio, and G. Meroni Genomic analysis of the TRIM family reveals two groups of genes with distinct evolutionary properties BMC Evol Biol 8 2008 225
4. K. Ozato, D.M. Shin, T.H. Chang, and H.C. Morse III TRIM family proteins and their emerging roles in innate immunity Nat Rev Immunol 8 2008 849 860
5. French FMF Consortium A candidate gene for familial Mediterranean fever Nat Genet 17 1997 25 31
6. N.A. Quaderi, S. Schweiger, and K. Gaudenz Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22 Nat Genet 17 1997 285 291
7. P. Frosk, T. Weiler, and E. Nylen Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene Am J Hum Genet 70 2002 663 672
8. K. Avela, M. Lipsanen-Nyman, and N. Idanheimo Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism Nat Genet 25 2000 298 301
9. M. Stremlau, C.M. Owens, M.J. Perron, M. Kiessling, P. Autissier, and J. Sodroski The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys Nature 427 2004 848 853
10. M. Stremlau, M. Perron, and M. Lee Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor Proc Natl Acad Sci U S A 103 2006 5514 5519
11. S. Ohmine, R. Sakuma, T. Sakuma, T. Thatava, H. Takeuchi, and Y. Ikeda The antiviral spectra of TRIM5alpha orthologues and human TRIM family proteins against lentiviral production PLoS One 6 2011 e16121
12. H. de The, C. Lavau, A. Marchio, C. Chomienne, L. Degos, and A. Dejean The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR Cell 66 1991 675 684
13. A. Kakizuka, W.H. Miller Jr., and K. Umesono Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML Cell 66 1991 663 674
14. A.D. Goddard, J. Borrow, P.S. Freemont, and E. Solomon Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia Science 254 1991 1371 1374
15. M. Takahashi, Y. Inaguma, H. Hiai, and F. Hirose Developmentally regulated expression of a human "finger"-containing gene encoded by the 5' half of the ret transforming gene Mol Cell Biol 8 1988 1853 1856
16. B. Le Douarin, C. Zechel, and J.M. Garnier The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18 EMBO J 14 1995 2020 2033
17. K. Allton, A.K. Jain, and H.M. Herz Trim24 targets endogenous p53 for degradation Proc Natl Acad Sci U S A 106 2009 11612 11616
18. W.W. Tsai, Z. Wang, and T.T. Yiu TRIM24 links a non-canonical histone signature to breast cancer Nature 468 2010 927 932
19. T. Urano, T. Saito, and T. Tsukui Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth Nature 417 2002 871 875
20. K. Khetchoumian, M. Teletin, and J. Tisserand Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha Nat Genet 39 2007 1500 1506
21. S.T. Lott, N. Chen, and D.S. Chandler DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer PLoS Med 6 2009 e1000068
22. S.M. Kornblau, N. Singh, Y. Qiu, W. Chen, N. Zhang, and K.R. Coombes Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia Clin Cancer Res 16 2010 1865 1874
23. S.M. Kornblau, M. Womble, and Y.H. Qiu Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia Blood 108 2006 2358 2365
24. S.M. Kornblau, R. Tibes, and Y.H. Qiu Functional proteomic profiling of AML predicts response and survival Blood 113 2009 154 164
25. R. Tibes, Y. Qiu, and Y. Lu Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells Mol Cancer Ther 5 2006 2512 2521
26. B. Hunyady, K. Krempels, G. Harta, and E. Mezey Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining J Histochem Cytochem 44 1996 1353 1362
27. J. Hu, X. He, K.A. Baggerly, K.R. Coombes, B.T. Hennessy, and G.B. Mills Non-parametric quantification of protein lysate arrays Bioinformatics 23 2007 1986 1994
28. E.S. Neeley, K.A. Baggerly, and S.M. Kornblau Surface adjustment of reverse phase protein arrays using positive control spots Cancer Inform 11 2012 77 86
29. R.F. Schlenk, K. Dohner, and J. Krauter Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1909 1918
30. R.E. Gale, C. Green, and C. Allen The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia Blood 111 2008 2776 2784
31. S. Kayser, R.F. Schlenk, and M.C. Londono Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome Blood 114 2009 2386 2392
32. U. Bacher, C. Haferlach, W. Kern, T. Haferlach, and S. Schnittger Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients Blood 111 2008 2527 2537
33. K. Dohner, R.F. Schlenk, and M. Habdank Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations Blood 106 2005 3740 3746
34. R.G. Verhaak, C.S. Goudswaard, and W. van Putten Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance Blood 106 2005 3747 3754
35. S. Schnittger, C. Schoch, and W. Kern Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Blood 106 2005 3733 3739
36. C. Thiede, S. Koch, and E. Creutzig Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) Blood 107 2006 4011 4020
37. R. Brosh, and V. Rotter When mutants gain new powers: news from the mutant p53 field Nat Rev Cancer 9 2009 701 713
38. D. Vilimek, and V. Duronio Cytokine-stimulated phosphorylation of GSK-3 is primarily dependent upon PKCs, not PKB Biochem Cell Biol 84 2006 20 29
39. Z. Wang, K.S. Smith, M. Murphy, O. Piloto, T.C. Somervaille, and M.L. Cleary Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy Nature 455 2008 1205 1209
40. Y. Wang, A.V. Krivtsov, and A.U. Sinha The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML Science 327 2010 1650 1653
41. Y. Wang, Y. Liu, S.N. Malek, and P. Zheng Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies Cell Stem Cell 8 2011 399 411
42. L.M. Napolitano, E.G. Jaffray, R.T. Hay, and G. Meroni Functional interactions between ubiquitin E2 enzymes and TRIM proteins Biochem J 434 2011 309 319
43. L. Xu, L. Yang, and P.K. Moitra BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5delta Exp Cell Res 288 2003 84 93
44. A. Trockenbacher, V. Suckow, and J. Foerster MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation Nat Genet 29 2001 287 294
45. E.J. Horn, A. Albor, and Y. Liu RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties Carcinogenesis 25 2004 157 167
46. A. Vichi, D.M. Payne, G. Pacheco-Rodriguez, J. Moss, and M. Vaughan E3 ubiquitin ligase activity of the trifunctional ARD1 (ADP-ribosylation factor domain protein 1) Proc Natl Acad Sci U S A 102 2005 1945 1950